Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls

John B. Christoforidis, Zhiliang Xie, Angela Jiang, Jillian Wang, Cedric Pratt, Anne Gemensky-Metzler, Mahmoud Abdel-Rasoul, Sashwati Roy, Zhongfa Liu

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Purpose: To determine serum level differences of intravitreally-placed bevacizumab after vitrectomy and lensectomy-vitrectomy and to compare these with non-operated eyes in a rabbit model. Methods: Five Dutch-belted rabbits underwent pars plana vitrectomy (PPV), five rabbits underwent pars plana lensectomy (PPL) and five rabbits served as non-surgical controls. Twelve days following the surgical procedures, each operated eye underwent an intravitreal injection consisting of 1.25 mg/0.05 mL bevacizumab. Serum levels from each rabbit were drawn on days 2, 4, 7, 10, 14, 21, 28 and 35 and were measured with ELISA immunoassay. Results: The average peak serum concentration (Cmax) was highest for the PPL group (11.33 μg ± 3.48 mL), and was similar between the PPV (5.35 μg ± 2.69 mL) and non-surgical control groups (5.35 μg ± 0.69 mL). The average time to maximal plasma concentration (Tmax) in days was earliest for the PPL group (2.8 ± 0.47), followed by the PPV (5.6 ± 0.84) and non-surgical control groups (6.4 ± 0.71). The PPL group had higher serum levels than the other two groups until day 7 that was significant only at day 2 (p < 0.0001). After day 4, there were no significant differences or trends between any of the three groups. The half-life (T1/2) was fastest for the PPL group (1.41 ± 0.21 d) followed by the PPV (2.80 ± 3.35 d) and non-surgical control groups (6.69 ± 10.4 d). Conclusions: Serum bevacizumab levels were initially elevated following lensectomy and vitrectomy compared to non-surgical eyes following intravitreal injection. The half-life of bevacizumab was prolonged in non-surgical eyes presumably due to a slower release from the vitreous cavity.

Original languageEnglish (US)
Pages (from-to)761-766
Number of pages6
JournalCurrent Eye Research
Issue number7
StatePublished - 2013


  • Bevacizumab
  • Lensectomy
  • Pharmacokinetics
  • Serum
  • Vascular endothelial growth factor
  • Vitrectomy

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls'. Together they form a unique fingerprint.

Cite this